Bluechiip, a global leader in advanced sample management solutions for harsh environments is proud to announce a licence, development and supply agreement with US based BioLife Solutions, a market leader in bioproduction tools and services for Cell and Gene Therapy (CGT). The partnership represents a major milestone for the industry by combining Bluechiip's unique technology into BioLife's proprietary primary packaging containers for the CGT market.
BioLife will gain global exclusive use of Bluechiip technology in primary containers in CGT technology manufacturing and final dose. Bluechiip is expected to be incorporated into BioLife’s range of CellSeal and CryoCase final packaging containers. BioLife will also have non-exclusive access to distribute Bluechip’s existing product range and Bluechiip will continue to sell its existing products used across multiple applications supporting current and new customers with its highly differentiated advanced sample management solution.
BioLife Solutions is recognised as a leading provider of bioproduction tools and services for the CGT market, supporting hundreds of clinical applications. Their products represent the gold standard in maintaining the viability of biologics through manufacturing, storage, and distribution, vital to CGT production and delivery.
Roderick de Greef, Chairman and CEO of BioLife Solutions, said: “We are delighted to enter the Agreement to utilise the unique Bluechiip technology in the critical CGT market. Bluechiip’s technology provides the potential for BioLife to further differentiate our products in the critical temperature sensitive environments of cell and gene therapy.”
Andrew McLellan, Managing Director of Bluechiip, commented: “We are excited to work alongside BioLife Solutions, a market leader in CGT tools and services. The partnership is a transformative step in our strategic vision and provides significant validation for Bluechiip’s technology in the rapidly expanding CGT market, a market valued at over $17 billion and growing at over 20% annually. Cryopreservation is paramount in the CGT market and Bluechiip’s unique capabilities in the cryogenic field of both traceability and temperature are critical to this.”